Company: APM
Filing Date: 2025-12-05
Form Type: 424B5
Source: 0001213900-25-118752
Chunk: 217

Company: Aptorum Group Ltd
Filing Date: 2025-12-05
Form: 424B5
Chunk 217
---
paired student’s t-test, p<0.05 |

Figure 2: Result of study on ALS-4’s effect in the healing of
open wounds infected with MRSA in a mouse model

In a further round of in vivostudies, conducted by a third-party
contract research organization, in a non-lethal MRSA bacteraemia mouse model, the mice were orally administered with different doses of
ALS-4 from 0.3 to 30mg/kg twice a day for 7 days, compared to those who received vancomycin only group (3mg/kg of vancomycin
administered intravenously) and a no treatment control group.

At the conclusion of the study on Day 7, ALS-4 brought a statistically
significant reduction in bacterial counts in major organs such as the kidneys, lungs, liver and spleen compared with the no drug control
and vancomycin only groups (unpaired student’s t-test, p<0.05). This is in addition to the previous in vivoresults announced
in February 2020.

Body weight monitoring and histopathological evaluation of major organs
were conducted as preliminary safety indicators. According to the histopathology evaluation conducted by the contract research organization,
no significant differences in severity of lesions in lungs were observed in ALS-4 and vancomycin groups compared to vehicle group (p >
0.05 by unpaired Student’s t-test). Similarly, there was no statistical difference in severity of lesions between test articles
and non-infected groups or between test articles and vehicle groups (p > 0.05 by unpaired Student’s t-test) in kidney assessments.
These studies were designed to establish proof-of-concept and generate efficacy data, with comprehensive toxicology assessments subsequently
completed during the IND-enabling studies phase.

<div align='center'>118</div>

ALS-4 demonstrated on a statistically
significant basis better survival rates (56% vs 0% control group) in the lethal MRSA bacteraemia rat model (Figure 3a) and higher reduction
of bacterial load (by 99.5% against the control group) in the non-lethal MRSA bacteraemia rat model (Figure 3b).

Figure 3a

Figure 3a: Oral Formulation
of ALS-4 in an MRSA Survival Study

Figure 3b

Figure 3b: Oral Formulation
of ALS-4 in a Non-Lethal Bacteremia Model

CFU